Expert Panel Expands Recommended H.I.V. Prevention Options

Influential expert panel gave its highest recommendation to expanded menu of H.I.V. prevention strategies for adults and adolescents.
Recommendation requires private insurers to cover the drugs without co-pay or deductible under Affordable Care Act.
Panel recommended three medications approved for pre-exposure prophylaxis (PrEP): Truvada, Descovy, and cabotegravir.
New options may cost over $20,000 per year.
In 2020, nearly 31,000 people acquired H.I.V., with majority of cases among adolescent and adult men who have sex with men.